Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 51.5% in December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 832,200 shares, a growth of 51.5% from the November 30th total of 549,400 shares. Based on an average trading volume of 78,700 shares, the days-to-cover ratio is presently 10.6 days. Approximately 3.8% of the shares of the stock are sold short.

Gyre Therapeutics Trading Down 5.2 %

GYRE stock opened at $12.45 on Monday. The company has a 50 day simple moving average of $12.71 and a 200 day simple moving average of $12.66. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $27.45.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the 2nd quarter worth $218,000. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the second quarter worth about $123,000. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics in the second quarter valued at approximately $220,000. Renaissance Technologies LLC bought a new position in Gyre Therapeutics in the 2nd quarter valued at approximately $166,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the period. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.